ClinicalTrials.gg
Active, not recruitingNCT03654053SACREDUpdated Nov 19, 2026

Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis

A Phase 3 interventional study of Placebo Oral Tablet and Simvastatin 40mg in Cirrhosis, sponsored by VA Office of Research and Development. Active, not recruiting at 11 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Primary conditionFibrosis(the registry's first term)UnverifiedIs this wrong?Fibrosis is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by VA Office of Research and Development · Phase 3, Interventional, and Treatment

How we know

Updated Nov 19, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This phase III, randomized, double-blind, placebo-controlled, multi-center study seeks to test whether simvastatin, a statin usually used to lower cholesterol to prevent heart problems and strokes, can lower the risk of hepatic decompensation (developing symptoms of cirrhosis) in U.S. Veterans who have compensated cirrhosis (the liver is scarred and damaged but there are no symptoms). The study will also explore how changes or differences in genes effect the safety and effectiveness of using statins and how the use of statins affects quality of life.

Read the detailed description

HMG-coA reductase inhibitors (statins), independent of cholesterol-lowering effects, are beneficial in liver diseases by reducing endothelial dysfunction, intrahepatic vasoconstriction, inflammation and fibrosis, and can reduce portal vein blood pressure. Clinically significant portal hypertension (hepatic vein wedge pressure greater than or equal to 10mmHg) is the most important predictor of decompensation and death in patients with cirrhosis.

This randomized, double-blind, placebo-controlled, multi-center Phase III interventional study seeks to demonstrate that statin therapy in patients with cirrhosis at high-risk for hepatic decompensation will reduce the incidence of hepatic decompensation, hepatocellular carcinoma or all-cause mortality.

Patients with compensated cirrhosis at high-risk for hepatic decompensation will be stratified based on the presence or absence of varices and randomized to simvastatin 40mg/day for up to 24 months. Patients will be observed for the development of hepatic decompensation (variceal hemorrhage, ascites, encephalopathy), hepatocellular carcinoma, liver-related death, death from any cause, and/or complications of statin therapy. Additionally, the interaction of SLCO1B1 and KIF6 polymorphisms on safety and clinical efficacy of statin therapy and the impact of statin exposure on health-related quality of life in patients with compensated cirrhosis will be examined.

02

Conditions studied

  • Cirrhosis

Browse trials for

Keywords

  • cirrhosis
  • hepatic decompensation
  • HMG-coA reductase
  • hepatocellular carcinoma
  • clinical trial
  • Human
03

In context

Fibrosis Unverified

1,272 studies on the registry are indexed under Fibrosis; 278 are open to participants now.

This study's enrollment of 142 is above the median of 64 across 842 interventional studies indexed under Fibrosis.

Browse Fibrosis studies →

Lead sponsor

VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.

Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.

Compared within Fibrosis, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • U.S. Veteran
  • Cirrhosis due to chronic viral hepatitis, or alcohol or non-alcoholic fatty liver
  • Compensated cirrhosis (history of endoscopically-confirmed variceal hemorrhage, absence of overt ascites, history of overt non-precipitated encephalopathy)
  • Age > 18 and \<= 80
  • High risk of cirrhosis decompensation as defined by any of the following:

    • Presence of esophageal varices on endoscopy
    • Presence of portosystemic collaterals on imaging as determined by a body radiologist
    • Fibroscan VCTE >= 20kPa
    • count \<= 125 K/mm
    • 44 total points (\~50% of portal hypertension using the ANTICIPATE Nomogram)
  • Competent to provide

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to any statin within 6 months
  • Prior allergy or sensitivity to simvastatin
  • History of variceal hemorrhage confirmed endoscopically within the previous 3 years
  • Presence of overt ascites or treatment with diuretics for ascites with 6 months
  • History of chronic, recurrent or episodic overt hepatic encephalopathy with asterixis within 6 months
  • History of hepatocellular carcinoma
  • Child-Turcotte-Pugh C Stage (CTP Score > 9)
  • Prior receipt of organ transplant
  • Participation in another pharmacological clinical trial within 3 months of the current study
  • Pregnancy or anticipated pregnancy within 2 years
  • Breast Feeding
  • Patients with \< 3 years due to comorbid conditions
  • Independent indication for initiation of statin therapy
  • Patients with any form of clinical atherosclerotic cardiovascular disease (ASCVD)
  • Patients with primary LDL-C \< 190 mg/dl
  • Patients with diabetes mellitus, age 40-75 years, with LDL-C levels >=130 mg/dl
  • Need for concomitant administration of potent inhibitors of CYP34A4 enzymes (medications or other supplements that should not be taken with simvastatin, including cyclosporine, danazol, gemfibrozil, fenofibrate, extended release niacin, itraconazole, ketoconazole, voriconazole, protease inhibitors, boceprevir, telaprevir, macrolide antibiotics - erythromycin, clarithromycin, telithromycin, nefazadone, amlodipine, verapamil, diltiazem, dronedarone, amiodarone, renolazine, lomitapide, and cobicistat)
  • Prior TIPSS shunt
  • Hemodialysis
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    Simvastatin

    Simvastatin 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.

    Drug: Simvastatin 40mg

  • Placebo comparator
    Placebo

    Placebo 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.

    Drug: Placebo Oral Tablet

Interventions

  • DrugPlacebo Oral Tablet

    Placebo taken once nightly at bed time.

    Also known as: Placebo

  • DrugSimvastatinStudies of SimvastatinSimvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Simvastatin 40mg taken once nightly at bed time.

    Also known as: Simvastatin

06

What researchers measure

Primary outcomes

  1. Survival free from hepatic decompensation

    Occurrence of hepatic decompensation measured by first variceal hemorrhage, or development of ascites, or onset of hepatic encephalopathy, or hepatocellular carcinoma.

    Time frame: 24 months

Secondary outcomes

  1. Liver-related death

    Occurrence of death after hepatic decompensation, or hepatocellular carcinoma or transplantation

    Time frame: 24 months

  2. Survival free from major cardiac events

    Occurrence of acute myocardial infarction, or unstable angina, or acute ischemic stroke, or coronary revascularization.

    Time frame: 24 months

  3. Change in patient health-related quality of life

    Clinically significant change in score from baseline to month 12 as assessed by the PROMIS-29 questionnaire

    Time frame: 12 months

  4. Statin-related hepatotoxicity

    Occurrence of hepatotoxicity defined as Grade 3 liver toxicity per CTCAE 5.0 ( 5 times upper limit of normal as defined by local laboratory- transaminases)

    Time frame: 24 months

  5. Myositis

    Occurrence of myositis defined as either Grade 3 myositis (pain associated with severe weakness; limiting self care Activities Daily Living {ADL}) OR Grade 4 creatine phosphokinase by CTCAE 5.0 ( 10x upper limit of normal)

    Time frame: 24 months

  6. Rhabdomyolysis

    Occurrence of rhabdomyolysis defined as Grade 3 (symptomatic, urgent intervention indicated)

    Time frame: 24 months

  7. Hepatotoxicity

    Liver enzyme testing (AST, ALT, alkaline phosphatase, total bilirubin) at each study visit.

    Time frame: 24 months

07

Study locations

11 sites
08

References and documents

Publications

  • Kaplan DE, Mehta R, Garcia-Tsao G, Albrecht J, Aytaman A, Baffy G, Bajaj J, Hernaez R, Hunt K, Ioannou G, Johnson K, Kanwal F, Lee TH, Monto A, Pandya P, Schaubel D, Taddei TH. SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. Contemp Clin Trials. 2021 May;104:106367. doi: 10.1016/j.cct.2021.106367. Epub 2021 Mar 24. PubMed 33771685 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Deidentified data will be shared upon request following completion of a DUA for purposes of verification and meta-analysis.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Following closure of study database

Access criteria: Data use / data transfer agreement

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Dec 2026, 74 months after the start.

Of 52 phase 3 interventional studies under Fibrosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 70. This study's planned 74 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2018
First posted
Aug 31, 2018
StartActual
Oct 2, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Richmond VA Medical Center, Richmond, VA · Richmond, United States
Show 1 removed
  • Hunter Holmes McGuire VA Medical Center, Richmond, VA · Richmond, United States
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    1 site added, 1 site removed
    Show site
    • Richmond VA Medical Center, Richmond, VA · Richmond, United States
    Show 1 removed
    • Hunter Holmes McGuire VA Medical Center, Richmond, VA · Richmond, United States
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03654053
Responsible party
Sponsor
First posted
Aug 31, 2018
Start date
Oct 2, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 19, 2026

Study contacts

David E. Kaplan, MD MSc
principal investigator · Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Simvastatin

Start the discussion